cysteine has been researched along with exenatide in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, N; Luo, XS; Ma, AN; Wang, YX; Xu, M; Zhang, LJ; Zhang, YH | 1 |
| Cao, F; Chen, X; Gao, H; Guo, N; Hida, N; Huang, X; Kiesewetter, DO; Lang, L; Niu, G; Wang, H; Zhang, X | 1 |
| Chen, X; Guo, J; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Sun, Z; Yue, X; Zhang, X; Zhu, L | 1 |
| Dong, H; Gao, X; Guo, L; Hu, X; Qian, X; Tian, H; Tong, Y; Yao, W | 1 |
| Chen, F; Liu, P; Luo, S; Pan, D; Sun, X; Wang, L; Xu, Q; Xu, Y; Yang, M; Yang, R; Zhu, C | 1 |
| Mi, B; Pan, D; Wan, W; Wang, L; Wu, Y; Xu, Y; Yang, M; Yang, R; Yu, C | 1 |
| Bao, J; Gao, X; Ge, Y; Luo, C; Sai, W; Song, X; Tang, D; Tian, H; Yang, K; Yao, W; Zhang, Y | 1 |
| Liu, Y; Pan, D; Sheng, J; Wang, L; Wang, X; Xu, Y; Yan, J; Yang, M; Yang, R | 1 |
| Chen, ZZ; Dushay, J; Gerszten, RE; Heineman, B; Kasid, N; Maratos-Flier, E; Migdal, AL; Nath, AK; Ngo, L; Phan, M; Rodgers, M; RodrÃguez, TG; Toschi, E; Tripaldi, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for cysteine and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for cysteine and exenatide
| Article | Year |
|---|---|
Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Combined Modality Therapy; Cysteine; Diet, Reducing; Double-Blind Method; Exenatide; Female; Humans; Metabolomics; Middle Aged; Obesity; Overweight; Treatment Outcome; Weight Loss | 2021 |
8 other study(ies) available for cysteine and exenatide
| Article | Year |
|---|---|
Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity.
Topics: Amino Acid Sequence; Animals; Blood Glucose; Cyclic AMP; Cysteine; Diabetes Mellitus, Experimental; Exenatide; Hypoglycemic Agents; Male; Mice; Molecular Sequence Data; PC12 Cells; Peptides; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tyrosine; Venoms | 2011 |
PET of glucagonlike peptide receptor upregulation after myocardial ischemia or reperfusion injury.
Topics: Animals; Cysteine; Exenatide; Glucagon-Like Peptide-1 Receptor; Male; Maleimides; Myocardial Reperfusion Injury; Peptides; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Time Factors; Up-Regulation; Venoms | 2012 |
Development of a new thiol site-specific prosthetic group and its conjugation with [Cys(40)]-exendin-4 for in vivo targeting of insulinomas.
Topics: Animals; Cell Line, Tumor; Cysteine; Exenatide; Female; Insulinoma; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Peptides; Sulfhydryl Compounds; Tissue Distribution; Venoms | 2013 |
Characterization of a site-specific PEGylated analog of exendin-4 and determination of the PEGylation site.
Topics: Amino Acid Sequence; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Cysteine; Electrophoresis, Polyacrylamide Gel; Exenatide; Maleimides; Molecular Sequence Data; Peptide Mapping; Peptides; Polyethylene Glycols; Protein Conformation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Technology, Pharmaceutical; Venoms | 2013 |
Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
Topics: Animals; Cell Line, Tumor; Cysteine; Drug Stability; Exenatide; Female; Fluorine Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Insulinoma; Maleimides; Mice; Mice, Nude; Pancreatic Neoplasms; Peptides; Positron-Emission Tomography; Rats; Venoms | 2015 |
Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4.
Topics: Animals; Cysteine; Diabetes Mellitus; Exenatide; Glucagon-Like Peptide-1 Receptor; Isotope Labeling; Male; Molecular Imaging; Organ Specificity; Pancreas; Peptides; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Venoms; Whole Body Imaging | 2016 |
Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Cyclic AMP; Cysteine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Intestine, Small; Male; Mice; Mutation; Peptide Hydrolases; Peptides; Protein Binding; Proteolysis; Signal Transduction; Structure-Activity Relationship; Trypsin; Venoms | 2017 |
Age-related change of GLP-1R expression in rats can be detected by [
Topics: Age Factors; Animals; Cysteine; Exenatide; Female; Fluorine Radioisotopes; Glucagon-Like Peptide-1 Receptor; Heterocyclic Compounds, 1-Ring; Male; Maleimides; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Tissue Distribution | 2018 |